Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company’s New Drug Application (NDA) for Duobrii1 (halobetasol propionate and tazarotene) (IDP-118) lotion in the treatment of plaque psoriasis. “The CRL did not specify any deficiencies related to the clinical efficacy…
